Mason Carrico
Stock Analyst at Stephens & Co.
(1.07)
# 3,564
Out of 4,843 analysts
81
Total ratings
26.47%
Success rate
-10.94%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Reiterates: Overweight | $67 | $41.30 | +62.25% | 2 | May 22, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $82.24 | +27.68% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $0.96 | +86.78% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $9.53 | +46.90% | 6 | May 15, 2025 | |
| HOLX Hologic | Maintains: Overweight | $77 → $70 | $62.17 | +12.59% | 4 | May 13, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $16.99 | +135.43% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $94.29 | +21.96% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $26.61 | +69.11% | 7 | Mar 26, 2025 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $3.32 | +20.48% | 5 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $40.62 | +35.40% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.25 | +44.00% | 6 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.77 | +116.61% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $17.81 | -4.55% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $34.39 | +51.21% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $4.19 | +377.33% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $15.97 | +156.73% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $157.73 | -20.75% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $7.27 | +161.35% | 1 | Jul 30, 2024 |
Vericel
May 22, 2025
Reiterates: Overweight
Price Target: $67
Current: $41.30
Upside: +62.25%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $82.24
Upside: +27.68%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $0.96
Upside: +86.78%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $9.53
Upside: +46.90%
Hologic
May 13, 2025
Maintains: Overweight
Price Target: $77 → $70
Current: $62.17
Upside: +12.59%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $16.99
Upside: +135.43%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $94.29
Upside: +21.96%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $26.61
Upside: +69.11%
OncoCyte
Mar 26, 2025
Reiterates: Equal-Weight
Price Target: $4
Current: $3.32
Upside: +20.48%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $40.62
Upside: +35.40%
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.25
Upside: +44.00%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.77
Upside: +116.61%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $17.81
Upside: -4.55%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $34.39
Upside: +51.21%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $4.19
Upside: +377.33%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $15.97
Upside: +156.73%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $157.73
Upside: -20.75%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $7.27
Upside: +161.35%